MedTrace Logo

Alpha Lipoic Acid and Diabetes Mellitus: Potential Effects on Peripheral Neuropathy

NCT04322240 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2020-12-30

No results posted yet for this study

Summary

Patients with type 2 DM who are following will be enrolled into the study. Two visits were scheduled for data collection, physical examination and laboratory testing of the patients: the first prior to initiation of alpha lipoic acid (ALA) administration (baseline visit) and the second at the end of the third month following initiation of ALA (2nd visit).

Conditions

  • Diabetic Polyneuropathy
  • Diabetes Mellitus, Type 2

Interventions

DRUG

Alpha lipoic acid

Participants will be prescribed 600 mg/day ALA (thiotacid) orally, for 3 months, and will be advised not to discontinue this medication

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Amira Mohamady, MD · Benha university- Qaluibya- Egypt

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-02
Primary Completion
2020-10-23
Completion
2020-12-23

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04322240 on ClinicalTrials.gov